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Background: The metastasis-associated in colon cancer 1 (MACC1) gene has been identified as prognostic biomarker
for colorectal cancer (CRC). Here, we aimed at the refinement of risk assessment by separate and combined survival
analyses of MACC1 expression with any of the markers KRAS mutated in codon 12 (KRAS G12) or codon 13 (KRAS G13),
BRAF V600 mutation and MSI status in a retrospective study of 99 CRC patients with tumors UICC staged I, II and III.
Findings: We showed that only high MACC1 expression (HR: 6.09, 95% CI: 2.50-14.85, P < 0.001) and KRAS G13
mutation (HR: 5.19, 95% CI: 1.06-25.45, P = 0.042) were independent prognostic markers for shorter metastasis-free
survival (MFS). Accordingly, Cox regression analysis revealed that patients with high MACC1 expression and KRAS
G13 mutation exhibited the worst prognosis (HR: 14.48, 95% CI: 3.37-62.18, P < 0.001). Patients were classified
based on their molecular characteristics into four clusters with significant differences in MFS (P = 0.003) by using
the SPSS 2-step cluster function and Kaplan-Meier survival analysis.
Conclusion: According to our results, patients with high MACC1 expression and mutated KRAS G13 exhibited
the highest risk for metachronous metastases formation. Moreover, we demonstrated that the “Traditional
pathway” with an intermediate risk for metastasis formation can be further subdivided by assessing MACC1
expression into a low and high risk group with regard to MFS prognosis. This is the first report showing that
identification of CRC patients at high risk for metastasis is possible by assessing MACC1 expression in
combination with KRAS G13 mutation.
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Background
Colorectal cancer (CRC) is the third most common can-
cer worldwide [1]. According to the state of the art for
classification, colorectal carcinoma can be divided into
three major pathways based on the underlying molecular
alterations [2,3]. The majority of CRC belong to the
“Traditional pathway” which reflects the adenoma-
carcinoma sequence model [4,5]. Two additional* Correspondence: ustein@mdc-berlin.de
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unless otherwise stated.pathways where recently described, the “Serrated” and
“Alternate pathway” [2-4], which are characterized by
differences in the microsatellite instability (MSI) status
and mutations in the KRAS or BRAF oncogenes. In ad-
vanced stages metastatic spread shortens the 5-year sur-
vival rate from 90% to 10% [6,7]. Risk estimation by
using genetic factors for early identification of high risk
patients is still limited [8].
One promising candidate is the metastasis-associated in
colon cancer 1 (MACC1) gene. MACC1 is an important
prognostic marker for metastases formation in CRC [9,10].
Other promising molecular markers are oncogenic
KRAS mutations, which are detectable in 30-50% of
CRC tumors [11]. The most frequent point mutations in
codon 12 (KRAS G12) and 13 (KRAS G13) of exon 2s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stream pathways [12]. Although the role of KRAS muta-
tions as predictive biomarkers for anti-EGFR-targeted
therapy is well characterized, there is a need to clarify
their relevance as prognostic biomarkers for recurrence
of metastatic CRC [13].
In this retrospective study, we attempted to improve
the prognostic value of MACC1 for CRC metastasis
using separate and combined survival analyses of
MACC1 expression levels and KRAS G12 or G13 muta-
tions in tumors of CRC patients. In addition, we investi-
gated the prognostic significance of BRAF V600
mutation and MSI status, two of the most promising
prognostic and predictive markers in the landscape of
molecular biomarkers.Associations of MACC1 expression with the KRAS G12,
KRAS G13 and BRAF V600 mutations as well as MSI status
In total, 99 patients with patho-histologically confirmed
primary colorectal adenocarcinomas with Union for Inter-
national Cancer Control (UICC) stages I, II and III were
included in this study. This patient study protocol was
approved by the Institutional Review Board (IRB) of the
Charité Universitätsmedizin Berlin, complied with the
Helsinki Declaration. The median metastasis-free sur-
vival (MFS) time and overall survival (OS) time of the
patients were 56.0 and 79.4 months, respectively. This
tumor marker study based on hypothesis-driven ap-
proaches was designed in compliance with the REMARK
guidelines [14]. MACC1 mRNA expression level of the
tumors were quantified using quantitative reverse tran-
scriptase PCR [9]. All patient and tumor characteristics
are shown in detail in the Additional file 1: Table S1–S4.
For KRAS and BRAF mutation analyses as well as MSI
status determination DNA sequencing methods were
used [15,16]. All used material and methods are de-
scribed in detail in Additional file 2. The molecular char-
acteristics in this cohort (Additional file 1: Table S2)
demonstrate the general distribution within colorectal
tumors and mutual exclusivity of the oncogenes KRAS
and BRAF [7,15].
MACC1 expression was significantly higher in primary
tumors of patients who developed metachronous metas-
tases during the follow-up period (P = 0.009; Figure 1A),
which confirmed previously described coherences [9,10].
We showed for the first time a correlation of high
MACC1 expression with tumors harboring KRAS mu-
tations (G12 or G13) (P = 0.049; Figure 1B) [7]. Separ-
ate analyses of primary tumors harboring the KRAS
G13 mutation exhibited a significantly higher MACC1
expression (P = 0.010; Figure 1D), but not for KRAS
G12 mutated tumors (P = 0.156; Figure 1C). High
MACC1 expression also correlated with BRAF wildtype (wt) (P = 0.027; Figure 1E) and microsatellite stable
(MSS)/MSI-Low (MSI-L) (P = 0.009; Figure 1F) tumors.Association of MACC1 expression, KRAS G12 or G13
mutation, BRAF mutation and MSI status with MFS
We performed Kaplan-Meier survival analyses (Figure 2)
and univariate Cox regression to estimate hazard ratios
(HR) and 95% confidence intervals (CI) for the associ-
ation of the tumor characteristics with MFS (Additional
file 1: Table S5). Interestingly, univariate Cox regression
and Log Rank test revealed that in the set of analyzed
markers, only high MACC1 expression levels and KRAS
G13 mutation emerged as prognostic factors for MFS.
Patients with high MACC1 expression levels (Figure 2A,
Log Rank P < 0.001; Cox regression: low vs. high, HR:
5.02, 95% CI: 2.19-11.53, P < 0.001) or KRAS G13 muta-
tion (Figure 2D, Log Rank P = 0.022; Cox regression: wt
vs. KRAS G13, HR: 4.25, 95% CI: 1.21-14.93, P = 0.024)
in their primary tumors exhibited a significantly poorer
prognosis. Although the role of KRAS G13 mutation as
a predictive biomarker for anti-EGFR-targeted therapy
[18] is well characterized, the prognostic value of KRAS
G13 mutation in patients with CRC is controversial [19].
Various reports either encourage or dismiss KRAS muta-
tions as prognostic biomarker for disease-specific survival
rates or to predict liver or lung metastases [7,19-24]. Data
of the Kirsten Ras in Colorectal Cancer Collaborative
Group Studies (RASCAL I) suggested that the risk of re-
currence and death is increased by the presence of KRAS
mutations [11], and the updated RASCAL II study con-
fined the correlation of KRAS mutation and survival prog-
nosis to the G12V mutation [25]. According to our
results, comparison of mutated KRAS tumors with KRAS
wt tumors had no significant impact on MFS (Figure 2B,
Log Rank P = 0.499; Cox regression: wt vs. KRAS G12 or
G13, HR: 1.40, 95% CI: 0.63-3.09, P = 0.409). Studies com-
paring the effects of KRAS G12 with KRAS G13 muta-
tions are rare [19,24]. Therefore separate analyses of
KRAS G12 and KRAS G13 mutations in the tumors were
included and demonstrated that especially the KRAS G13,
but not KRAS G12 (Figure 2C, Log Rank P = 0.654; Cox
regression: wt vs. KRAS G12, HR: 1.29, 95% CI: 0.55-3.03,
P = 0.556), mutations were prognostic for reduced MFS.
Separate analyses of the most prominent G12 mutations
(G12V, G12D and G12C) revealed no significant impact of
these mutations on MFS prognosis (Log Rank P = 0.826,
P = 0.896 and P = 0.766; respectively). Furthermore, BRAF
V600 mutation (Figure 2E, Log Rank P = 0.656; Cox re-
gression: wt vs. BRAF V600, HR: 0.75, 95% CI: 0.18-3.17,
P = 0.694) or MSS/MSI-L (Figure 2F, Log Rank P = 0.085;
Cox regression: MSS/MSI-L vs. MSI-H, HR: 0.04, 95%




Figure 1 Associations of MACC1 expression with KRAS mutation, BRAF mutation or MSI status. MACC1 mRNA expression levels of the
tumors were quantified using quantitative reverse transcriptase PCR [9]. Tumor DNA was extracted and subjected to PCR for amplification of KRAS
and BRAF sequences and analyzed by sequencing [15]. MSI Analysis System was used for MSI status determination as described previously [16].
Tumors were discriminated in Microsatellite stable (MSS)/MSI-low (MSI-L; 0 or 1 markers demonstrating instability) or MSI-High (MSI-H; two or
more markers instable). A Significantly increased MACC1 mRNA expression levels were detected in primary tumors of patients with metachronous
metastases (P = 0.009). B MACC1 expression level was significantly increased in KRAS mutated (G12 or G13) tumors compared to tumors with
KRAS wild type (KRAS wt) (P = 0.049). C There were no significant differences of MACC1 expression in KRAS G12 mutated compared to KRAS wt
tumors (P = 0.156). D Primary tumors harboring G13 mutated KRAS showed a significantly increased MACC1 expression level (P = 0.010). E In BRAF
wt tumors MACC1 expression was significantly increased compared to BRAF V600 mutated tumors (P = 0.027). F MACC1 expression of MSS/MSI-L
tumors was significantly increased compared to MSI-H tumors (P = 0.009). Significance in differential mRNA expression was determined by
Mann–Whitney U-test. Calculation of q-values from the corresponding P-values was performed to control for the false discovery rate (FDR)
[17]. FDR-adjusted P-values less than 0.05 were considered to be statistically significant.
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KRAS G12 or G13 mutation with tumor characteristics
Next, we analyzed the effects of clinicopathological
parameters like age, gender, UICC stage, grading and
postoperative treatment of the tumors concerning
MFS in combination with MACC1 or KRAS muta-
tions using multivariate Cox regression (Table 1).
Only high MACC1 expression (HR: 6.09, 95% CI:
2.50-14.85, P < 0.001) and KRAS G13 mutation (HR:
5.19, 95% CI: 1.06-25.45, P = 0.042) turned out to be
independent prognostic markers for shorter MFS inthe set of analyzed biomarkers. To our knowledge,
this is the first study showing a prognostic relevance
of KRAS G13 for MFS in CRC patients and
demonstrating KRAS G13 mutation as independent
risk factor of age, gender, UICC stage, grading and
postoperative treatment for metachronous metasta-
ses development.
In addition, we performed multivariate Cox regres-
sion combining MACC1 expression level with the
tumor characteristics KRAS G12 or G13 mutation,





Figure 2 Patients’ metastasis-free survival prognosis according to MACC1 mRNA expression, KRAS mutation, BRAF mutation and MSI
status. The Kaplan–Meier method was used to estimate cumulative survival rates. MFS time was defined as the time period from the date of
surgery to the date of confirmed distant metastases or to the date of last follow-up contact/death for censored patients. A Patients with high
MACC1 expression exhibited a statistically significant reduced MFS (P < 0.001). B No significant differences of MFS between KRAS mutated (G12 or
G13) and KRAS wt tumors (P = 0.499) were detected. C KRAS G12 mutation showed no significant impact on MFS prognosis (P = 0.654). D MFS of
patients with KRAS G13 mutated tumors compared to patients with KRAS wt was significantly reduced (P = 0.022). E There was no significant impact of
BRAF V600 mutation on MFS prognosis (P = 0.656). F In MSS/MSI-L tumors we observed a tendency of shorter MFS (P = 0.085) compared to
MSI-H tumors, but differences were not significant. G Tumors with high MACC1 expression and KRAS G13 exhibited the shortest MFS (mean:
19.0 months) compared to tumors with high MACC1 expression and KRAS wt (mean: 88.7 months, P = 0.039). Significance of differences in
survival rates were assessed using the Log Rank test. P-values less than 0.05 were considered to be statistically significant.
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P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI)
Molecular Markers MACC1 (low vs. high)
KRAS G12/G13 (wt vs. mutated)
<0.001 6.09 (2.50-14.85) 0.302 1.55 (0.67-3.59) 0.042 5.19 (1.06-25.45) 0.543 1.34 (0.52-3.42)
Age at diagnosis (<60) vs. (>60) years 0.970 1.02 (0.41-2.52) 0.892 0.94 (0.39-2.26) 0.648 1.30 (0.43-3.93) 0.940 1.04 (0.37-2.90)
By gender Male vs. Female 0.890 0.94 (0.41-2.17) 0.969 1.02 (0.44-2.34) 0.494 1.42 (0.52-3.91) 0.963 0.98 (0.41-2.35)
UICC stage (I) vs. (II + III) 0.473 1.65 (0.42-6.53) 0.191 2.42 (0.64-9.09) 0.356 2.16 (0.42-11.10) 0.115 3.59 (0.73-17.54)
By grading (G1 + 2) vs. (G3 + 4) 0.416 0.64 (0.22-1.88) 0.257 0.53 (0.18-1.59) 0.305 0.45 (0.10-2.06) 0.094 0.28 (0.06-1.24)
By postoperative treatment Untreated
vs. treated
0.064 2.37 (0.95-5.93) 0.447 1.40 (0.59-3.29) 0.723 1.22 (0.41-3.57) 0.483 1.39 (0.55-3.49)
The P-values, hazard ratios (HR) and 95% confidence intervals (CI) of different parameters concerning MFS were calculated using Cox regression analyses. The analysis
was performed separately for each factor with the parameters listed in the table being introduced as covariates, respectively.
A B
C
Figure 3 Classification of CRC patients with regard to their molecular characterization. A Integrative 2-step cluster analyses allowed the
differentiation of four clusters with regard to their tumor characteristics. Clustering of the tumors concerning KRAS G13 mutation, MACC1 expression,
BRAF V600 mutation and MSI status was performed by the SPSS 2-step cluster function. The order of the molecular markers represents the significance
of the predictor was determined by the 2- step cluster analysis function. †MSS: includes MSS/MSI-L samples. B Kaplan-Meier survival analysis revealed
significantly different survival times for the four clusters (P = 0.003). Patients of Cluster 1 had the best prognosis and patients in Cluster 4 had the worst
prognosis. C According to Leggett and Whitehall [2] Cluster 1 (in blue) represents the “Serrated pathway” which is characterized by the lowest risk
(10%) for metastasis formation. Cluster 2 and Cluster 3 belong to the “Traditional pathway” (in green) with intermediate risk for metastasis formation.
Here, we show that MACC1 expression subdivides this cluster into a low risk (16%, light green) and high risk (45%, dark green) group. The highest risk
(60%) patients were classified in Cluster 4 representing the “Alternate pathway” (in red). According to our results these tumors are now characterized
by a high MACC1 expression and mutated KRAS G13.
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statistically significant independent for MFS progno-
sis of these molecular markers (HR: 4.20, 95% CI:
1.80-9.81, P = 0.001). Therefore, we conducted com-
binatorial survival prognosis of the independent
prognostic markers MACC1 expression and KRAS
G13 mutation. Interestingly, patients with the worst
prognosis were characterized by high MACC1 ex-
pression and KRAS G13 mutation (HR: 14.48, 95%
CI: 3.37-62.18, P < 0.001). These patients had the short-
est MFS time (Figure 2G, Log Rank: P = 0.039 mean:
18.99 months, 95% CI: 10.64-27.34) compared to
patients with high MACC1 expression and KRAS wt
tumors (Additional file 1: Table S6). The identification
of CRC patients at high risk for metastasis formation is
possible by assessing MACC1 expression in combin-
ation with KRAS G13 mutations.Cluster classification
Using integrative 2-step cluster analysis based on the
presence of the proven markers in our cohort four
clusters of patients with a different risk for metasta-
sis formation could be distinguished and coincide
well with the presumed pathways (Figure 3). Accord-
ing to CRC classification by Leggett and Whitehall
[2], Cluster 1 represents the “Serrated pathway” with
MSI-H, BRAF mutation and low MACC1 expression.
These patients showed the lowest risk for metachro-
nous metastases formation. In our study Cluster 2
and 3 represents the “Traditional pathway”, where
the majority of CRC cases belong to. This pathway
is characterized by MSS and KRAS or BRAF muta-
tion. Cluster 2 with a low risk for metastasis forma-
tion was further characterized by low MACC1
expression. In contrast, Cluster 3 with increased risk
exhibited high MACC1 expression levels. Thus,
MACC1 expression allows a further subdivision of
the “Traditional pathway” into a low and high risk
group of patients concerning metastasis formation.
Patients in Cluster 4 had the highest risk for meta-
chronous metastases development. These tumors
belonging to the “Alternate pathway” were defined
by MSI-L/MSS, KRAS G13 mutation and can be fur-
ther characterized by high MACC1 expression.Conclusion
This exploratory study has limitations especially due to
the limited number of patient samples. But this cohort
has also several strengths: The marker analyses were
performed with microdissected cryosections verified by
an experienced pathologist. Furthermore the studied
cohort is very well characterized and only samples
from preoperatively untreated patients with very longfollow-up data and complete clinicopathological infor-
mation were used.
In conclusion, our results underline the high relevance
of MACC1 and KRAS G13 mutation for CRC metastasis
prognosis. This is the first study showing a prognostic
relevance of KRAS G13 for MFS in CRC patients. Fur-
thermore, high MACC1 expression and KRAS G13
mutation are independent prognostic markers for
metachronous metastases development. Accordingly,
combinatorial survival prognosis revealed that patients
with high MACC1 expression and KRAS G13 mutation
exhibited the worst prognosis.
Interestingly, the conventional CRC classification can
be extended and refined by inclusion of MACC1 expres-
sion and mutated KRAS G13 as independent markers.
Therefore, this refinement allows improved individual-
ized prognosis and intervention strategies for the
majority of CRC patients in clinical routine.
Consent
Written informed consent was obtained from the pa-
tient for the publication of this report and any accom-
panying images.
Additional files
Additional file 1: Supplementary Tables. Table S1. Patient
characteristics with regard to MACC1 expression and the determined
relative risk (RR) with corresponding 95% confidence intervals (CI) are
shown. Table S2. The frequencies of mutations and MSI status of the
tumors and corresponding MACC1 expression are shown. Table S3.
Contains the localization of the metachronous, distant metastases of
the patients within the cohort. Table S4. The frequencies of postoperative
treatment within the patient cohort are shown. Table S5. Includes the
univariate and multivariate Cox regression analyses of the analyzed biomarkers.
The analysis was performed separately for each factor with the parameters
listed in the table being introduced as covariates, respectively. Table S6.
Includes the MFS time and P-values for the analyzed biomarkers were
calculated using the Kaplan–Meier survival analyses and the Log Rank test.
Additional file 2: Materials and methods. This file includes detailed
information regarding tumor specimens, RNA and DNA isolation,
mutations analysis, MSI status determination and statistical analysis.
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